The Gene Therapy R&D Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments, and a Promising Pipeline Reshaping Medicine’s Future

In the past five years, gene therapy has made a remarkable comeback. Advancements in virology, vector and capsid architecture, and manufacturing have led to exciting breakthroughs and regulatory progress, capturing the attention of biotech investors. Biopharma firms are strategizing to gain an edge, expanding facilities, forming partnerships, and collaborating with contract manufacturing organizations (CMOs).

According to a recent report by the Alliance for Regenerative Medicine, over 1,400 global companies are focused on cell and gene therapies (CGTs), with 3,500 therapies in development and over 2,000 active clinical trials. North America leads in clinical trials, followed by the Asia Pacific and Europe, with oncology and rare diseases as the primary therapeutic targets. Venture capital remains the main driver of growth, reflecting enthusiasm for scientific advancements and potential treatment breakthroughs.

The FDA expects to receive over 200 investigational new drug applications for CGTs annually, approving 10 to 20 new therapies per year. In 2024, up to 21 cell therapy and 31 gene therapy launches are anticipated, prompting the FDA to elevate its Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Research and Evaluation (CBER). Proposed structural changes aim to enhance review capabilities and expertise to accommodate the growing workload and ensure efficient regulatory processes.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the gene therapy R&D market evolving?
  • What is driving and restraining the gene therapy R&D market?
  • How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each gene therapy R&D submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the gene therapy R&D projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of
    gene therapy R&D projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
  • Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the gene therapy R&D market today, and over the next 10 years:

  • Our 340-page report provides 156 tables and 192 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the gene therapy R&D market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Disease

  • Cancer
  • Rare Diseases
    – Oncologic
    – Non-oncologic
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Haematology
  • Neurological
  • Diabetes Mellitus
  • Other Diseases

Vector

  • Viral
    – Retrovirus
    – Adenovirus
    – AAV
    – Lentivirus
    – Others
  • Non-viral
    – Naked DNA
    – Gene Gun
    – Electroporation
    – Lipofection

Techniques

  • Gene Augmentation Therapy
  • Gene Replacement Therapy

Participants

  • Small/Medium Pharma & Biotech
  • Universities & Research Institutes
  • Hospitals
  • Government & Public Bodies
  • Big Pharma

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA